Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy

Area of Science:

• Pharmacogenomics
• Drug Metabolism
• Antifungal Therapy

Background:

• Voriconazole, a crucial triazole antifungal, exhibits significant interpatient variability in serum concentrations.
• Genetic variations in the CYP2C19 enzyme are a key factor influencing this variability.
• CYP2C19 genotype impacts voriconazole metabolism, affecting drug efficacy and safety.

Purpose of the Study:

• To review the scientific literature linking CYP2C19 genetic variations to voriconazole serum concentrations.
• To provide evidence-based therapeutic recommendations for voriconazole use tailored to CYP2C19 genotype.

Main Methods:

• Literature review of studies investigating the association between CYP2C19 alleles and voriconazole pharmacokinetics.
• Analysis of data on trough voriconazole concentrations in relation to CYP2C19 metabolizer status.
• Synthesis of evidence to inform clinical practice guidelines.

Main Results:

• CYP2C19 ultrarapid metabolizers show decreased voriconazole trough concentrations, potentially delaying therapeutic efficacy.
• CYP2C19 poor metabolizers exhibit increased voriconazole trough concentrations, elevating the risk of adverse drug events.
• A clear correlation exists between specific CYP2C19 genotypes and voriconazole pharmacokinetics.

Conclusions:

• CYP2C19 genotyping is essential for optimizing voriconazole therapy.
• Personalized dosing strategies based on CYP2C19 genotype can improve voriconazole treatment outcomes.
• Clinical practice guidelines should incorporate pharmacogenetic information for voriconazole prescribing.